| Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches JA Welsh, DCI Goberdhan, L O'Driscoll, EI Buzas, C Blenkiron, ... Journal of extracellular vesicles 13 (2), e12404, 2024 | 997 | 2024 |
| Bone marrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy D Forte, M García-Fernández, A Sanchez-Aguilera, V Stavropoulou, ... Cell metabolism 32 (5), 829-843. e9, 2020 | 173 | 2020 |
| The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling D Forte, V Salvestrini, G Corradi, L Rossi, L Catani, RM Lemoli, M Cavo, ... Oncotarget 8 (2), 2261, 2016 | 66 | 2016 |
| Updates on the hematologic tumor microenvironment and its therapeutic targeting D Forte, DS Krause, M Andreeff, D Bonnet, S Méndez-Ferrer Haematologica 104 (10), 1928, 2019 | 48 | 2019 |
| Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis M Romano, D Sollazzo, S Trabanelli, M Barone, N Polverelli, M Perricone, ... Oncoimmunology 6 (10), e1345402, 2017 | 46 | 2017 |
| Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn’s disease patients in a mouse model … D Forte, M Ciciarello, MC Valerii, L De Fazio, E Cavazza, R Giordano, ... Stem Cell Research & Therapy 6, 1-16, 2015 | 45 | 2015 |
| The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis M Barone, L Catani, F Ricci, M Romano, D Forte, G Auteri, D Bartoletti, ... Oncoimmunology 9 (1), 1782575, 2020 | 31 | 2020 |
| Circulating calreticulin is increased in myelofibrosis: correlation with interleukin‐6 plasma levels, bone marrow fibrosis, and splenomegaly D Sollazzo, D Forte, N Polverelli, M Perricone, M Romano, S Luatti, ... Mediators of inflammation 2016 (1), 5860657, 2016 | 30 | 2016 |
| The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling L Rossi, D Forte, G Migliardi, V Salvestrini, M Buzzi, MR Ricciardi, ... Experimental hematology 43 (11), 974-985. e1, 2015 | 30 | 2015 |
| Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study D Sollazzo, D Forte, N Polverelli, M Romano, M Perricone, L Rossi, ... Oncotarget 7 (28), 43974, 2016 | 27 | 2016 |
| Denatonium as a bitter taste receptor agonist modifies transcriptomic profile and functions of acute myeloid leukemia cells V Salvestrini, M Ciciarello, V Pensato, G Simonetti, MA Laginestra, ... Frontiers in oncology 10, 1225, 2020 | 26 | 2020 |
| The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study M Perricone, N Polverelli, G Martinelli, L Catani, E Ottaviani, E Zuffa, ... Oncotarget 8 (23), 37239, 2017 | 26 | 2017 |
| The more, the better:“do the right thing” for natural killer immunotherapy in acute myeloid leukemia S Parisi, M Lecciso, D Ocadlikova, V Salvestrini, M Ciciarello, D Forte, ... Frontiers in immunology 8, 1330, 2017 | 25 | 2017 |
| Emerging bone marrow microenvironment-driven mechanisms of drug resistance in acute myeloid leukemia: tangle or chance? M Ciciarello, G Corradi, D Forte, M Cavo, A Curti Cancers 13 (21), 5319, 2021 | 24 | 2021 |
| Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis. M Barone, F Ricci, D Sollazzo, E Ottaviani, M Romano, G Auteri, ... Wiley, 2019 | 22 | 2019 |
| Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: real‐world data F Palandri, M Breccia, M Tiribelli, M Bonifacio, G Benevolo, A Iurlo, EM Elli, ... Hematological Oncology 38 (3), 372-380, 2020 | 18 | 2020 |
| A venetoclax and azacitidine bridge‐to‐transplant strategy for NPM1‐mutated acute myeloid leukaemia in molecular failure C Sartor, L Brunetti, E Audisio, A Cignetti, L Zannoni, G Cristiano, J Nanni, ... British Journal of Haematology 202 (3), 599-607, 2023 | 17 | 2023 |
| Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive … D Forte, M Barone, C Morsiani, G Simonetti, F Fabbri, S Bruno, E Bandini, ... Journal of Experimental & Clinical Cancer Research 40, 1-14, 2021 | 16 | 2021 |
| KAT2A complexes ATAC and SAGA play unique roles in cell maintenance and identity in hematopoiesis and leukemia L Arede, E Foerner, S Wind, R Kulkarni, AF Domingues, G Giotopoulos, ... Blood advances 6 (1), 165-180, 2022 | 14 | 2022 |
| The “Vesicular intelligence” strategy of blood cancers D Forte, M Barone, F Palandri, L Catani Genes 12 (3), 416, 2021 | 12 | 2021 |
